

PERSONAL INFORMATION

Marta Brambilla

POSITION

05/11/2020 – today

Medical Oncologist, Department of Medical Oncology

Foundation IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy

Thoracic Cancer Unit

WORK EXPERIENCE

05/11/2020 – today

Medical Oncologist, Department of Medical Oncology

Foundation IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy

Thoracic Cancer Unit

01/11/2017 – 04/11/2020

Specialist registrar, Department of Medical Oncology

Foundation IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy

Thoracic Cancer Unit, Gastro-Intestinal Cancer Unit, Breast cancer Unit, Melanoma Unit

Specialist registrar, Department of Medical Oncology

01/11/2015 – 31/10/2017

Santa Maria della Misericordia Hospital and University of Perugia, Italy

Thoracic Cancer Unit, Internal Medicine ward

2006 – 2008

Lifeguard in private swimming pool

EDUCATION AND TRAINING

01/04/2022 – today

Master II level: Methods and Data Analysis in Biomedical Research (MEDAL)

University of Milan-Bicocca

15/02/2021 – 13/04/2021

Advanced course in clinical research

Systematic reviews and meta-analysis

01/11/2017 – 04/11/2020

Specialist registrar, Department of Medical Oncology

Degree in Medical Oncology (70/70 cum laude)

Thesis Title: Circulating and tumor associated neutrophil subtypes in hyperprogressive disease upon immune checkpoint inhibitors in advanced non-small cell lung cancer patients.

Foundation IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy

Thoracic Cancer Unit, Gastro-Intestinal Cancer Unit, Breast cancer Unit, Melanoma Unit

23/03/2019 – 28/03/2019

18th ESO-ESMO Masterclass in Clinical Oncology

Nauen OT Gross Berhnitz

01/11/2015 – 31/10/2017

Specialist registrar, Department of Medical Oncology

Santa Maria della Misericordia Hospital and University of Perugia, Italy

Thoracic Cancer Unit, Internal Medicine ward

September 2008 – March 2015

Bachelor in Medicine and Surgery

First Class Degree (108/110)

Thesis Title: Phase II clinical trial with Temozolomide in metastatic colorectal cancer selected according to *MGMT* gene silencing.

University of Milano-Bicocca, Faculty of Medicine and Surgery, Monza, Italy

December 2013 – March 2015

Internship in Oncology

Division of Oncology, Niguarda Ca' Granda Hospital, Milano, Italy

October 2012

Internship in Oncology

Division of Oncology, San Gerardo Hospital, Monza, Italy

July 2012

Internship in Clinical Research

Division of Clinical Research, San Gerardo Hospital, Monza, Italy

September 2003– June 2008

Secondary School Diploma

High School of Science Antonio Banfi, Vimercate, Monza e Brianza, Italy

SCIENTIFIC AFFILIATIONS

August 2019 – today

Member of FONICAP

ID number 000174

November 2017 – today

Member of ESMO

ID number 409688

November 2017 – today

Member of AIOM

22/07/2015

Member of Italian Medical Association

Medical Association of Monza and Brianza, ID number 03967

09/07/2015

Board certified in Medicine and Surgery

PERSONAL SKILLS

Mother tongue(s)

Italian

Other language(s)

UNDERSTANDING

SPEAKING

WRITING

Listening

Reading

Spoken interaction

Spoken production

English

B2

B2

B2

B2

B2

French

A2

A2

A2

A2

A2

Communication skills

Good communication and presentation skills gained through my scholastic experiences.

Organizational / managerial skills

Excellent managerial skills gained through my experience of supervisor of Young Component of Red Cross Organization of Monza division.

Excellent organizational skills gained through the activity of planning fund-raising campaign and promoting events as a referent member of Young Component of Red Cross Organization of Monza division.

Digital competence

SELF-ASSESSMENT

Information processing	Communication	Content creation	Safety	Problem solving
Independent User	Independent user	Independent user	Independent user	Basic user

Microsoft Windows and Mac OS X Operative Systems. Microsoft Office Suite, in particular Word, Excel and Powerpoint. Good ability using Internet both as a tool of communication and to search scientific information. Use of Medline database, e.g. Pubmed.

Driving licence

B

SCIENTIFIC INVOLVMENT

Publications

Galli, G., Corsetto, P. A., Proto, C., Lo Russo, G., Ganzinelli, M., Rulli, E., Legramandi, L., Morelli, D., Ferrara, R., Prelaj, A., Signorelli, D., De Toma, A., Brambilla, M., Occhipinti, M., Manglaviti, S., Boeri, M., Martinetti, A., Vingiani, A., Colombo, M. P., Rizzo, A. M., ... Garassino, M. C. (2022). Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer. *Clinical lung cancer*, 23(7), e489–e499. <https://doi.org/10.1016/j.clcc.2022.07.010>

Brunelli, C., Zecca, E., Pigni, A., Bracchi, P., Caputo, M., Lo Dico, S., Fusetti, V., Tallarita, A., Bergamini, C., Brambilla, M., Raimondi, A., Niger, M., Provenzano, S., Sepe, P., Alfieri, S., Tinè, G., De Braud, F., & Caraceni, A. T. (2022). Outpatient palliative care referral system (PCRS) for patients with advanced cancer: an impact evaluation protocol. *BMJ open*, 12(10), e059410. <https://doi.org/10.1136/bmjopen-2021-059410>

Signorelli, D., Ghidotti, P., Proto, C., Brambilla, M., De Toma, A., Ferrara, R., Galli, G., Ganzinelli, M., Lorusso, G., Prelaj, A., Occhipinti, M., Viscardi, G., Capizzuto, V., Pontis, F., Petrarola, I., Ferretti, A. M., Colombo, M. P., Torri, V., Sozzi, G., Garassino, M. C., ... Fortunato, O. (2022). Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. *Frontiers in immunology*, 13, 987639. <https://doi.org/10.3389/fimmu.2022.987639>

Zattarin, E., Manglaviti, S., Apollonio, G., Beninato, T., Mazzeo, L., Massa, G., Bottiglieri, A., Galli, E., De Toma, A., Occhipinti, M., Brambilla, M., Ferrara, R., Ganzinelli, M., Proto, C., Garassino, M. C., de Braud, F., Lo Russo, G., & Prelaj, A. (2022). Prognostic role of neutrophil-to-lymphocyte ratio and EPSiLoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. *Future oncology (London, England)*, 18(23), 2593–2604. <https://doi.org/10.2217/fon-2021-1454>

Prelaj, A., Bottiglieri, A., Bhat, G., Washington, R., Calareso, G., Greco, G. F., Ferrara, R., Brambilla, M., De Toma, A., Occhipinti, M., Manglaviti, S., Soro, A., Ganzinelli, M., Lo Russo, G., & Proto, C. (2022). Case Report: Exceptional Response to Pozitotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation. *Frontiers in oncology*, 12, 902967. <https://doi.org/10.3389/fonc.2022.902967>

De Giglio, A., Di Federico, A., Deiana, C., Ricciuti, B., Brambilla, M., & Metro, G. (2022). Advanced non-small-cell lung cancer: how to manage non-oncogene disease. *Drugs in context*, 11, 2022-2-4. <https://doi.org/10.7573/dic.2022-2-4>

Metro, G., De Giglio, A., Ricciuti, B., Siringo, M., Marinelli, D., Gelibter, A., Pecci, F., Berardi, R., Cantini, L., Di Federico, A., Andriani, E., Mosca, M., Lamberti, G., Brambilla, M., & Mountzios, G. (2022). Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease. *Drugs in context*, 11, 2022-3-9. <https://doi.org/10.7573/dic.2022-3-9>

Zanella, C., Leone, A. G., Zambelli, L., Bottiglieri, A., Canziani, L., Brambilla, M., Lo Russo, G., Platania, M., De Braud, F., & Occhipinti, M. (2022). Paraneoplastic neurological syndromes in patients affected by SCLC: a case series. *Tumori*, 3008916221079663. Advance online publication. <https://doi.org/10.1177/03008916221079663>

Prelaj, A., Boeri, M., Robuschi, A., Ferrara, R., Proto, C., Lo Russo, G., Galli, G., De Toma, A., Brambilla, M., Occhipinti, M., Manglaviti, S., Beninato, T., Bottiglieri, A., Massa, G., Zattarin, E., Gallucci, R., Galli, E. G., Ganzinelli, M., Sozzi, G., de Braud, F. G. M., ... Trovo', F. (2022). Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy. *Cancers*, 14(2), 435. <https://doi.org/10.3390/cancers14020435>

Spagnoletti, A., Platania, M., Brambilla, M., Occhipinti, M., Canziani, L., Cabras, A., Provenzano, L., Leone, A. G., Ambrosini, P., & Prelaj, A. (2022). Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease. *Tumori*, 3008916211067565. Advance online publication. <https://doi.org/10.1177/03008916211067565>

S. Manglaviti, M. Brambilla, D. Signorelli, R. Ferrara, G. Lo Russo, C. Proto, G. Galli, A. De Toma, M. Occhipinti, G. Viscardi, T. Beninato, E. Zattarin, M. Bini, R. Lobefaro, G. Massa, A. Bottiglieri, G. Apollonio, E. Sottotetti, R.M. Di Mauro, B. Trevisan, et al, A. Prelaj. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology. *Clinical lung cancer*, **2021**, Jul. S1525-7304(21)00180-7. Advance online publication. <https://doi.org/10.1016/j.clcc.2021.06.013>

F. Corti, S. Lonardi, R. Intini, M. Salati, E. Fenocchio, C. Belli, B. Borelli, M. Brambilla, A.A. Prete, V. Quarà, M. Antista, M. Fassan, F. Morano, A. Spallanzani, M. Ambrosini, G. Curigliano, F. de Braud, V. Zagonel, G. Fucà, & F. Pietrantonio. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. *European journal of cancer (Oxford, England : 1990)*. **2021**, Jun. 150, 155–167. <https://doi.org/10.1016/j.ejca.2021.03.043>

M. Occhipinti, M. Brambilla, G. Galli, S. Manglaviti, M. Giammaruco, A. Prelaj, R. Ferrara, A. De Toma, C. Proto, T. Beninato, E. Zattarin, G. Lo Russo, A.J. Gelibter, M. Simmaco, R. Preissner, M.C. Garassino, F. De Braud, & P. Marchetti. Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. *Journal of personalized medicine*. **2021**, May. 11(5), 424. <https://doi.org/10.3390/jpm11050424>

A. Prelaj, A. Bottiglieri, C. Proto, G. Lo Russo, D. Signorelli, R. Ferrara, G. Galli, A. De Toma, G. Viscardi, M. Brambilla, R. Lobefaro, F. Nichetti, S. Manglaviti, M. Occhipinti, A. Labianca, M. Ganzinelli, R. Gallucci, N. Zilembo, G. F. Greco, V. Torri, et al, M.C. Garassino. Pozitotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. *European journal of cancer (Oxford, England : 1990)*. **2021**, May. 149, 235–248. <https://doi.org/10.1016/j.ejca.2021.02.038>

R. Lobefaro, G. Viscardi, R. Di Liello, G. Massa, M.L. Iacovino, F. Sparano, C.M. Della Corte, R. Ferrara, D. Signorelli, C. Proto, A. Prelaj, G. Galli, A. De Toma, M. Brambilla, M. Ganzinelli, B. Trevisan, F. Ciardiello, F. De Braud, F. Morgillo, M.C. Garassino, G. Lo Russo. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. *Lung Cancer*. **2021**, Jan. Volume 152, Pages 165-173, ISSN 0169-5002, <https://doi.org/10.1016/j.lungcan.2020.12.027>.

M. Brambilla, G. Lo Russo, R. Ferrara, S. Manglaviti, M.C. Garassino, M. Occhipinti. Is hyperprogressive disease a specific phenomenon of immunotherapy? *Explor Target Antitumor Ther*. **2020**, Dec. 1:427-33. <https://doi.org/10.37349/etat.2020.00027>

G. Viscardi, D. Di Natale, M. Fasano, M. Brambilla, R. Lobefaro, A. De Toma, G. Galli. Circulating biomarkers in malignant pleural mesothelioma. *Explor Target Antitumor Ther*. **2020**, Dec. 1:434-51. <https://doi.org/10.37349/etat.2020.00028>

R. Lobefaro, E. Zattarin, F. Nichetti, M. Prisciandaro, F. Ligorio, M. Brambilla, P. Sepe, F. Corti, G. Peverelli, A. Ottini, T. Beninato, L. Mazzeo, C.G. Rea, G. Mariani, F. de Braud, G.V. Bianchi, C. Vernieri, G. Capri. Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis. *Ther Adv Med Oncol*. **2020**, Dec. 7;12:1758835920970081. doi: 10.1177/1758835920970081. PMID: 33335565; PMCID: PMC7724266

M. Niger, M. Prisciandaro, M. Antista, M.A.T. Monica, L. Cattaneo, N. Prinzi, S. Manglaviti, F. Nichetti, M. Brambilla, M. Torchio, F. Corti, S. Pusceddu, J. Coppa, V. Mazzaferro, F. de Braud, M. Di Bartolomeo. One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches. *World J Gastrointest Oncol*. **2020**, Aug 15;12(8):833-849. doi: 10.4251/wjgo.v12.i8.833. PMID: 32879662; PMCID: PMC7443847.

A. Prelaj, C. Proto, G. Lo Russo, D. Signorelli, R. Ferrara, M. Mensah, G. Galli, A. De Toma, G. Viscardi, M. Brambilla, R. Lobefaro, B. Trevisan, F. Trovò, V. Torri, G. Sozzi, M.C. Garassino, M. Boeri. Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMO score system. *Transl Lung Cancer Res.* **2020**, Jun;9(3):617-628. doi: 10.21037/tlcr-20-231. PMID: 32676324; PMCID: PMC7354114.

F. Corti, M. Brambilla, S. Manglaviti, L. Di Vico, M.N. Pisanu, C. Facchinetti, K.F. Dotti, R. Lanocita, A. Marchianò, F. de Braud, L.A.M. Ferrari. Comparison of outcomes of central venous catheters in patients with solid and hematologic neoplasms: an Italian real-world analysis. *Tumori*, **2020**, Jun 12:300891620931172. doi: 10.1177/0300891620931172. Epub ahead of print. PMID: 32529962.

G. Galli, A. Trama, L. Abate-Daga, M. Brambilla, M.C. Garassino, A. Fabbri. Accuracy of pathologic diagnosis for thymic epithelial tumors: a brief report from an Italian reference Center. *Lung Cancer*, **2020**, May. Volume 146, August 2020, Pages 66-69

C. Vernieri, M. Prisciandaro, F. Nichetti, R. Lobefaro, G. Peverelli, F. Ligorio, E. Zattarin, M.S. Cona, P. Sepe, F. Corti, S. Manglaviti, M. Brambilla, B. Re, C. Maggi, A. Belfiore, G. Pruneri, L. Celio, G. Mariani, G.V. Bianchi, L. Rivoltini, G. Capri, F. de Braud. Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. *Cancers*, Volume 12, Issue 3, **2020**, March. Article number 617

A. Prelaj, R. Ferrara, S.E. Rebuzzi, C. Proto, D. Signorelli, G. Galli, A. De Toma, G. Randon, F. Pagani, G. Viscardi, M. Brambilla, B. Trevisan, M. Ganzinelli, A. Martinetti, R. Gallucci, R.M. Di Mauro, G. Molino, N. Zilembo, V. Torri, F. de Braud, M.C. Garassino, G. Lo Russo. EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer A Validation Cohort. *Cancers*. **2019**, 11, 1954; doi.org/10.3390/cancers11121954

B. Ricciuti, G.C. Leonardi, M. Brambilla. Emerging Biomarkers in the Era of Personalized Cancer Medicine. *Disease Markers*, vol. **2019**, Article ID 5907238, 2 pages, 2019. doi.org/10.1155/2019/5907238.

C. Vernieri, M. Milano, M. Brambilla, A. Mennitto, C. Maggi, M.S. Cona, M. Prisciandaro, C. Fabbri, L. Celio, G. Mariani, G. Capri, G.V. Bianchi, F. de Braud. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives. *Critical Reviews in Oncology/Hematology*. **2019**, Jul;139:53-66; doi.org/10.1016/j.critrevonc.2019.05.001

B. Ricciuti, C. Genova, M. Bassanelli, A. De Giglio, M. Brambilla, G. Metro, S. Baglivo, M.G. Dal Bello, A. Ceribelli, F. Grossi, R. Chiari. Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. *Clin Lung Cancer*. **2019** May; 20(3):178-185.e2. doi.org/10.1016/j.clcc.2019.02.001. Epub 2019 Feb 27.

C. Vernieri, M. Prisciandaro, M. Brambilla, C. Fabbri, A. Mennitto, E. Farè, G. Capri, L. Celio, G.V. Bianchi, M. Milano, C. Maggi, M.S. Cona, G. Mariani, S. Cresta, F. De Braud. Single-agent gemcitabine versus carboplatin-gemcitabine in advanced breast cancer: a retrospective comparison of efficacy and safety profiles. *Clin Breast Cancer*. **2019** Apr;19(2):e306-e318; doi.org/10.1016/j.clbc.2018.12.004

B. Ricciuti, C. Genova, A. De Giglio, M. Bassanelli, M.G. Dal Bello, G. Metro, M. Brambilla, S. Baglivo, F. Grossi, R. Chiari. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. *J Cancer Res Clin Oncol*. **2019** Feb;145(2):479-485. doi.org/10.1007/s00432-018-2805-3. Epub 2018 Dec 1.

B. Ricciuti, M. Brambilla, A. Cortellini, A. De Giglio, C. Ficorella, A. Sidoni, G. Bellezza, L. Crinò, V. Ludovini, S. Baglivo, G. Metro, R. Chiari. Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. *Clin Transl Oncol*. **2019** Jul; doi.org/10.1007/s12094-019-02175-y

A. De Giglio, R. Porreca, M. Brambilla, G. Metro, E. Prosperi, G. Bellezza, M. Pirro, R. Chiari, B. Ricciuti. Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does Oncogene addiction matter? *Thrombosis Research*. **2018** Mar, 163, 51; doi.org/10.1016/j.thromres.2017.12.004

M. Bassanelli, D. Giannarelli, A.J. Gelibter, F.L. Cerere, R. Chiari, S. Giacinti, S. Scagnoli, M. Milella, B. Ricciuti, M. Roberto, V. Magri, V. Ferraresi, M. Brambilla, P. Marchetti, E. Cortesi, A. Ceribelli. Systemic effect of radiotherapy (RT) followed by programmed death 1 (PD-1) inhibitors in non-small-cell lung cancer (NSCLC). *Journal of Clinical Oncology*. **2018** 36(sup5S), abstr 177

Ricciuti B, Baglivo S, Ludovini V, Sidoni A, Metro G, Brambilla M, Siggillino A, Reda MS, Rebonato A, Maietini D, Chiari R. Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. *Lung Cancer*. **2018** Jun;120:70-74. doi: 10.1016/j.lungcan.2018.04.002. Epub 2018 Apr 3. PMID: 29748019.

B. Ricciuti, G. Metro, M. Brambilla, V. Ludovini, S. Baglivo, A. Siggillino, E. Prosperi, R. Chiari. Acquired resistance to afatinib due to T790M-positive squamous progression in EGFR mutant adenocarcinoma lung carcinoma. *Journal of Thoracic Oncology*. **2018** Jan, 13(1),e9; doi.org/10.1016/j.jtho.2017.08.025

B. Ricciuti, R. Chiari, F. R. Tofanetti, A. De Giglio, R. Porreca, M. Brambilla, I. Sperduti, G. Bellezza, C. Mencaroni, A. Siggillino, D. Zicari, A. Baldi, V. Ludovini, G. Metro. Efficacy of platinum-based chemotherapy in EGFR WT nonsquamous advanced non-small cell lung cancer (NSCLC) patients: association with KRAS mutation and thymidylate synthase (TS) levels. *Annals of Oncology*. **2017** Oct, abstr E14

B. Ricciuti, M. Brambilla, G. Metro, S. Baglivo, R. Matocci, M. Pirro, R. Chiari. Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. *Med Oncol*. **2017** Jun, 34(6),105.

B. Ricciuti, M. Brambilla, A. De Giglio, G. Metro, R. Porreca, R. Chiari, L. Paglialunga. Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand? *J Radiat Oncol*. **2017** Feb, 6, 11-19. 10.1007/s13566-017-0293-8

G. Metro, B. Ricciuti, M. Brambilla, S. Baglivo, I. Soli, E. Minenza, GC. Leonardi, A. D'arpino, D. Colabrese, M. Tazza, D. Zicari, V. Minotti, R. Chiari. The safety of nivolumab for the treatment of advanced non small cell lung cancer. *Expert Opin Drug Saf*. **2017** Jan;16(1),101; doi.org/10.1080/14740338.2017.1267725

B. Ricciuti, GC. Leonardi, N. Ravaioli, A. De Giglio, M. Brambilla, E. Prosperi, F. Ribacchi, ML. Meacci, L. Crinò, D. Maietini, R. Chiari, G. Metro. Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient. *J Breast Cancer*. **2016** Sep,19(3), 324; http://dx.doi.org/10.4048/jbc.2016.19.3.324

Clinical trial

Sub-Therapeutic Area	Title	Phase	Role	Year	Trial status
Thoracic Tumors	A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)	III	Sub-Inv	2022	Accrual
Thoracic Tumors	International registry on thoracic cancer patients with COVID-19 TERA-VOLT (Thoracic cancer international coVID 19 cOLlaboraTion)	Observ	Sub-Inv	2022	Accrual
Thoracic Tumors	BRIDGE trial: Phase II trial of durvalumab and chemotheRapy Induction followed by Durvalumab and radiotherapy in larGe volumE stage III NSCLC	II	Sub-Inv	2022	Accrual
Thoracic Tumors	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve	III	Sub-Inv	2022	Accrual

	Limited-Stage Small Cell Lung Cancer (LS-SCLC)				
Thoracic Tumors	Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK- 7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC	III	Sub-Inv	2022	Accrual
Thoracic Tumors	Interrogating circulating lung tumor cells to guide personalized therapies and identify novel targets to hit metastasis initiating cells	Observ	Sub-Inv	2022	Accrual
Thoracic Tumors	A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin- Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer PAPILLON	III	Sub-Inv	2022	Accrual
Thoracic Tumors	A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	III	Sub-Inv	2022	Accrual
Thoracic Tumors	Apollo 11, a consortium of centers involved in the care of lung cancer patients treated with innovative therapies: integration of real world data and translational research	Observ	Sub-Inv	2022	Accrual
Thoracic Tumors	Integrative science and artificial intelligence platform to individualize immunotherapy treatment in patients with lung malignancy: the I3LUNG study	Observ	Sub-Inv	2022	Accrual
Thoracic Tumors	A randomized, open-label phase 2/3 study comparing cobolimab + dostarlimab + docetaxel to dostarlimab + docetaxel to docetaxel alone in participants with advanced non-small cell lung cancer who have progressed on prior anti-pd-(l)1 therapy and chemotherapy (COSTAR LUNG)	II/III	Sub-Inv	2022	Accrual
Thoracic Tumors	HPD 1 line – Hyperprogressive disease upon first line immunecheckpoint blockade in advance NSCLC patients	Observ	Sub-Inv	2021	Accrual
Thoracic Tumors	A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation	III	Sub-Inv	2021	Accrual
Thoracic Tumors	A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with lung cancer or pleural mesothelioma	II	Sub-Inv	2021	Accrual
Thoracic Tumors	Evaluation of the analytical validity of "comprehensive genomic profiling" on circulating tumor DNA for the implementation of liquid biopsy in precision oncology		Sub-Inv	2021	Accrual
Thoracic Tumors	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	II	Sub-Inv	2020	Accrual
Thoracic Tumors	A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer	II	Sub-Inv	2020	Accrual
Thoracic Tumors	Gender Difference in side Effects of Immunotherapy: a possible clue to optimize cancer treatment (G-DEFINER)	Observ	Sub-Inv	2020	Accrual
Thoracic Tumors	Exploiting metformin plus/minus cyclic Fasting Mimicking Diet (FMD) to improve the efficacy of first line chemo-immunotherapy in advanced LKB1-inactive lung adenocarcinoma	II	Sub-Inv	2020	Accrual
Thoracic Tumors	MILES5 – A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC.	II	Sub-Inv	2020	Accrual
Thoracic Tumors	Improving treatment strategies in thymic epithelial tumors: all type collaborative effort		Sub-Inv	2020	Accrual
Thoracic Tumors	A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy	III	Sub-Inv	2020	Accrual

	Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)				
Thoracic Tumors	A Phase 3, Randomized, Double-Blind, Placebo- Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)	III	Sub-Inv	2020	Accrual
Thoracic Tumors	Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic nonsquamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors	III	Sub-Inv	2020	Accrual
Thoracic Tumors	A Phase II, Randomized, Open-label Platform Trial Utilizing all Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants		Sub-Inv	2020	Accrual
Thoracic Tumors	Phase II, open-label study of atezolizumab in a Cohort of pretreated, Advanced Non-small cell lung cancer (NSCLC) patients with rare histological subtypes (CHANCE trial)	II	Sub-Inv	2020	Closed
Thoracic Tumors	A phase III, multicenter, randomized, double blind, placebocontrolled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)	III	Sub-Inv	2020	Closed
Thoracic Tumors	A phase 2, multicenter, open-label, multicohort study to assess safety and efficacy of CC-90011 in combination with nivolumab in subjects with advanced cancers		Sub-Inv	2020	Closed
Thoracic Tumors	A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer (NSCLC)	Observ	Sub-Inv	2020	Closed
Thoracic Tumors	A randomized, phase 2, double-blind study to evaluate the efficacy of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy in metastatic non-squamous non-small cell lung cancer	III	Sub-Inv	2021	Closed
Thoracic Tumors	A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic nonsmall cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (LEAP-008)	III	Sub-Inv	2020	Closed
Thoracic Tumors	A phase IIIB, single arm, multicenter study of atezolizumab (tecentrig) in combination with carboplatin plus etoposide to investigate safety and efficacy in patients with untreated extensive-stage small cell lung cancer - MAURIS	III	Sub-Inv	2020	Closed
Thoracic Tumors	A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C	III	Sub-Inv	2020	Closed
Thoracic Tumors	PHASE 3 randomized study of DS-1062a versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer without actionable genomic alterations (TROPION-lung01)	III	Sub-Inv	2020	Closed
Thoracic Tumors	A Phase 2, Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST)	II	Sub-Inv	2020	Closed
Thoracic Tumors	A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (INN Sotorasib) for the Treatment of	IV	Sub-Inv	2020	Closed

	Subjects in Selected European Countries with Previously Treated Locally Advanced and Unresectable or Metastatic Non-small Cell Lung Cancer with KRAS p.G12C Mutation				
Thoracic Tumors	A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)		Sub-Inv	2020	Closed
Thoracic Tumors	Phase II study to test Pembrolizumab (MK-3475) in first line treatment of advanced NSCLC patients with PD-L1 low tumors (<50%)_ PEOPLE TRIAL (Pembrolizumab in Pd-L1 low Expressors)		Sub-Inv	2020	Closed
Thoracic Tumors	A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)		Sub-Inv	2020	Closed
Thoracic Tumors	Stromal control of lung cancer seeding through fibroblast reprogramming (AIRC IG 21431)	Observ	Sub-Inv	2020	Closed
Thoracic Tumors	Phase II study to evaluate the activity and safety of Cabozantinib in pretreated, advanced RET-reArranged non-small cell lung cancer patients: CRETA trial		Sub-Inv	2020	Closed
Thoracic Tumors	A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2)		Sub-Inv	2021	Closed
Thoracic Tumors	A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer MARIPOSA		Sub-Inv	2020	Closed
Thoracic Tumors	HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFRmutated Non-Small Cell Lung Cancer (NSCLC) (Patritumab Deruxtecan in Subjects with Metastatic or Locally Advanced EGFR-mutated NSCLC)		Sub-Inv	2020	Closed
Thoracic Tumors	Phase II trial of sunitinib in patients with type b3 thymoma or thymic carcinoma in second and further lines (Style trial).		Sub-Inv	2020	Closed
Thoracic Tumors	First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy	Observ	Sub-Inv	2020	Closed
Colorectal Cancer	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status. The Arethusa trial.		Sub-Inv	2019	Closed
Biliary tract cancer	Phase II Study of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolerant to First-line Platinum-Based Chemotherapy		Sub-Inv	2019	Closed
Breast Cancer	Tulip: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer	III	Sub-Inv	2018	Closed
Breast Cancer	BioltaLEE A phase IIb, open-label, local, multicenter study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment with ribociclib and letrozole.	IIIB	Sub-Inv	2018	Closed
Thoracic Tumors	BeTeam: Italian observational study on second line treatment approaches for EGFR-mutated, progressing NSCLC patients in real word clinical practice.	Observ	Sub-Inv	2016	Closed

Il sottoscritto MARTA BRAMBILLA, ai sensi di quanto previsto dagli artt. 19, 46 e 47 del D.P.R. 445/2000, consapevole delle conseguenze derivanti in caso di rilascio di dichiarazioni false, dichiara sotto la propria responsabilità che tutte le eventuali fotocopie allegate alla domanda di partecipazione al pubblico concorso, sono conformi all'originale in suo possesso e che ogni dichiarazione resa risponde a verità.

In compliance with the GDPR and Italian Legislative Decree no. 196 dated 30/06/2003, I hereby authorize the recipient of this document to use and process my personal details for the purpose of recruiting and selecting staff and I confirm to be informed of my rights in accordance to art. 7 of the above mentioned Decree.

Milano, 12/12/2022